Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 307Lung Neoplasms 111Adenocarcinoma of Lung 23Non-Squamous Non-Small Cell Lung Cancer 21Neoplasms 21Adenocarcinoma, Bronchiolo-Alveolar 15Brain Neoplasms 14Neoplasm Metastasis 10Squamous Cell Carcinoma of Head and Neck 5Respiratory Tract Diseases 5Carcinoma 5Breast Neoplasms 5Adenocarcinoma 5Thoracic Neoplasms 4Recurrence 4Pancreatic Neoplasms 4NSCLC 4Colorectal Neoplasms 4Colonic Neoplasms 4Salivary Gland Neoplasms 3Respiratory Tract Neoplasms 3Rectal Neoplasms 3Lung Diseases 3Esthesioneuroblastoma, Olfactory 3Carcinoma, Squamous Cell 3Carcinoma, Renal Cell 3Thymoma 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Pleural Effusion, Malignant 2

Interventions

Cisplatin 6Pemetrexed 5cediranib 3Chemotherapy, Adjuvant 3Radiotherapy 2Neoadjuvant Therapy 2Gemcitabine 2vatalanib 1rilotumumab 1pembrolizumab 1belinostat 1Watchful Waiting 1Vinorelbine 1Talc 1Sorafenib 1Semaxinib 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Platinum 1Pharmacogenomic Testing 1Methotrexate 1Immunoenzyme Techniques 1Gefitinib 1Erlotinib Hydrochloride 1Dihematoporphyrin Ether 1Dasatinib 1Capecitabine 1Bevacizumab 1ARQ 197 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solitary Fibrous Tumor, Pleural × Erlotinib Hydrochloride × Thoracic × Clear all
NCT00039182 2013-01-24

Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung

National Cancer Institute (NCI)

Phase 2 Completed
55 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

Data powered by HemOnc (CC BY 4.0) Colophon âš¡